Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| 50 DMA Resistance | Bearish | -5.00% | |
| 20 DMA Support | Bullish | -5.00% | |
| Earnings Movers | Other | -5.00% | |
| Fell Below 50 DMA | Bearish | -3.93% | |
| 180 Bearish Setup | Bearish Swing Setup | -3.93% | |
| Crossed Above 50 DMA | Bullish | -9.04% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| Rose Above Previous Day's High | about 20 hours ago |
| 50 DMA Resistance | about 20 hours ago |
| Up 3% | about 20 hours ago |
| Down 1% | about 20 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 10/31/2024
Actinium Pharmaceuticals, Inc. Description
Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Immunology Natural Sciences Immunotherapy Antibodies Chemical Elements Monoclonal Antibodies Monoclonal Antibody Stem Cell Acute Myeloid Leukemia Transplantation Platform Technology Actinides Cancer Center Hematopoietic Stem Cell Iodine Bismuth Immunotherapy Technology Kettering Cancer Center Memorial Sloan
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.24 |
| 52 Week Low | 1.33 |
| Average Volume | 300,024 |
| 200-Day Moving Average | 5.72 |
| 50-Day Moving Average | 1.81 |
| 20-Day Moving Average | 1.74 |
| 10-Day Moving Average | 1.78 |
| Average True Range | 0.13 |
| RSI (14) | 43.82 |
| ADX | 18.56 |
| +DI | 17.73 |
| -DI | 21.70 |
| Chandelier Exit (Long, 3 ATRs) | 1.52 |
| Chandelier Exit (Short, 3 ATRs) | 1.88 |
| Upper Bollinger Bands | 1.91 |
| Lower Bollinger Band | 1.58 |
| Percent B (%b) | 0.4 |
| BandWidth | 18.96 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0238 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.97 | ||||
| Resistance 3 (R3) | 2.00 | 1.94 | 1.93 | ||
| Resistance 2 (R2) | 1.94 | 1.87 | 1.92 | 1.91 | |
| Resistance 1 (R1) | 1.82 | 1.83 | 1.79 | 1.80 | 1.90 |
| Pivot Point | 1.76 | 1.76 | 1.75 | 1.75 | 1.76 |
| Support 1 (S1) | 1.65 | 1.69 | 1.62 | 1.62 | 1.52 |
| Support 2 (S2) | 1.59 | 1.65 | 1.57 | 1.51 | |
| Support 3 (S3) | 1.47 | 1.59 | 1.49 | ||
| Support 4 (S4) | 1.45 |
